Next Investors logo grey

Australia to legalise medical cannabis starting from November

Published 28-OCT-2016 15:31 P.M.

|

3 minute read

Hey! Looks like you have stumbled on the section of our website where we have archived articles from our old business model.

In 2019 the original founding team returned to run Next Investors, we changed our business model to only write about stocks we carefully research and are invested in for the long term.

The below articles were written under our previous business model. We have kept these articles online here for your reference.

Our new mission is to build a high performing ASX micro cap investment portfolio and share our research, analysis and investment strategy with our readers.


Click Here to View Latest Articles

The medical space is on the verge of a major shift as medical cannabis is set to be legalised from the beginning of November.

The landmark decision by the Therapeutic Goods Administration will allow those prescribed medical cannabis to consume the plant, however maintain that the natural substance remain strictly controlled.

The decision by the TGA follows from the Federal Parliament’s ruling to change the Narcotics Drugs Act to allow cannabis to be legally grown in Australia if it’s for medical purposes.

It seems the public perception surrounding cannabis is shifting as people become educated on the benefits the plant heralds in the medical space, let alone all the other benefits it offers in other industries, such as the use of hemp, biofuels and food.

Clinical trials around the world are providing strong evidence that cannabis helps patients dealing with chronic pain, epilepsy and cancer with little to no side effects.

The cannabis plant can also be used to help stimulate appetite for those with HIV, treat inflammatory bowel disease and migraines.

If the evidence surrounding medical cannabis continues to come in positive it is likely that we will see the plant and its compounds tested on other illnesses.

The benefits of the cannabis plant continue beyond medicine

Further evidence breaking the stigma surrounding marijuana is Colorado and Washington’s decision to legalise the recreational use of the plant.

The two states have seen major revenue inflows derived from taxes on the newly created marijuana industry, a reduction in both crime and dependence on traditional prescription drugs, particularly with regards to pain management.

Now Canada is set to legalise marijuana for recreational use next year.

Uruguay passed laws to legalise the growing and use of the marijuana plant in 2013 which has seen positive benefits for country including reduced drug related crimes.

Portugal legalised marijuana 15 years ago in 2001 and has seen use of heavy drugs plummet and drug related crimes plunge since.

The once demonised plant, that was labelled by the Ronald Reagan administration as the most dangerous drug of its time, may soon be replacing many synthetic drugs currently on the market.

Perhaps Reagan was right, cannabis may be the most dangerous ‘drug’ but to who?

The coming decade may see a shift back towards natural plants and medicines in the treatment of diseases, rather than synthetic drugs.

The biggest crime committed may not be from people using the plant for medicinal purposes, but those who have kept such a medicinal plant from the public for so long.

Either way public opinion is shifting in favour for cannabis use in what will inevitably become a multi-billion dollar global industry going forward.

Investors may want to start looking at ways to gain exposure to the industry that is seemingly in its infancy.

Companies listed on the ASX that are involved with medical cannabis include:

MGC Pharma (ASX:MXC) – has a pharmaceutical line of products targeting acne, psoriasis and other common skin conditions using cannabis based products.

MMJ Phytotech (ASX:MMJ) – focused on medical cannabis delivery systems with two cannabis growing facilities located in Canada.

Creso Pharma (ASX:CPH) – focused on pharmaceutical grade cannabis, hemp-based products and nutraceuticals.

However note that these stocks are speculative, and a successful investment is no guarantee. Seek tailored professional advice before making an investment.



General Information Only

S3 Consortium Pty Ltd (S3, ‘we’, ‘us’, ‘our’) (CAR No. 433913) is a corporate authorised representative of LeMessurier Securities Pty Ltd (AFSL No. 296877). The information contained in this article is general information and is for informational purposes only. Any advice is general advice only. Any advice contained in this article does not constitute personal advice and S3 has not taken into consideration your personal objectives, financial situation or needs. Please seek your own independent professional advice before making any financial investment decision. Those persons acting upon information contained in this article do so entirely at their own risk.

Conflicts of Interest Notice

S3 and its associated entities may hold investments in companies featured in its articles, including through being paid in the securities of the companies we provide commentary on. We disclose the securities held in relation to a particular company that we provide commentary on. Refer to our Disclosure Policy for information on our self-imposed trading blackouts, hold conditions and de-risking (sell conditions) which seek to mitigate against any potential conflicts of interest.

Publication Notice and Disclaimer

The information contained in this article is current as at the publication date. At the time of publishing, the information contained in this article is based on sources which are available in the public domain that we consider to be reliable, and our own analysis of those sources. The views of the author may not reflect the views of the AFSL holder. Any decision by you to purchase securities in the companies featured in this article should be done so after you have sought your own independent professional advice regarding this information and made your own inquiries as to the validity of any information in this article.

Any forward-looking statements contained in this article are not guarantees or predictions of future performance, and involve known and unknown risks, uncertainties and other factors, many of which are beyond our control, and which may cause actual results or performance of companies featured to differ materially from those expressed in the statements contained in this article. S3 cannot and does not give any assurance that the results or performance expressed or implied by any forward-looking statements contained in this article will actually occur and readers are cautioned not to put undue reliance on forward-looking statements.

This article may include references to our past investing performance. Past performance is not a reliable indicator of our future investing performance.